Psychiatric Genetic Testing Ltd (PGT) is an advanced molecular diagnostic development company specialising in genetic testing for patients with psychiatric disorders. The company is based in London.
Who created the test?
The Clozapine Test from PGT has been developed by Professor David Taylor, Professor of Psychopharmacology at King’s College, London, and Director of Pharmacy and Pathology at the Maudsley Hospital. Professor Taylor is the author of over 350 peer-reviewed publications in journals such as the Lancet, BMJ, British Journal of Psychiatry and Journal of Clinical Psychiatry, which have been cited over 15,000 times.
He has also been the lead author of the Maudsley Prescribing Guidelines in Psychiatry since their inception in 1993. The Maudsley Guidelines have sold over 300,000 copies in thirteen editions and twelve languages.
The 14th edition is available from March 2021.
Our vision is one of better outcomes and improved lives for people with schizophrenia around the world. This will be achieved by overcoming barriers to the use of clozapine.
Our mission is to promote The Clozapine Test to support the wider and earlier use of clozapine. The test will enable the use of clozapine by more patients and their experience of clozapine treatment will be much improved compared with ‘blind’ treatment.